Is there a role for therapy after transplant?

Betül Oran

Journal: Best practice & research. Clinical haematology 2016;28(2-3):124-32

PMID: 26590769

Full Text on Elsevier Science View on PubMed

Abstract

Despite the steady increase in the number of stem cell transplants performed since 1980 and improvements in survival rates, disease relapse remains the major cause of death after HLA matched sibling and unrelated donor transplants for acute myeloid leukemia (AML). Given this situation, maintenance therapy after transplant may be an appropriate strategy to reduce the relapse rate and prolong survival. A number of agents are being investigated as maintenance therapy after stem cell transplant in AML patients, including azacitidine, decitabine, and other agents. This paper focuses on the role of maintenance treatment to reduce the risk of relapse after transplant.

Address: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA. Electronic address: [email protected].

DOI: 10.1016/j.beha.2015.10.009

Link outs

Free resources

Medical:

https://medlineplus.gov/acutemyeloidleukemia.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-DQA1...

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Azacitidine, Benzothiazoles, Decitabine, Hematopoietic Stem Cell Transplantation, Humans, Hydroxamic Acids, Indoles, Leukemia, Myeloid, Acute, Maintenance Chemotherapy, Niacinamide, Panobinostat, Phenylurea Compounds, Recurrence, Siblings, Sorafenib, Survival Analysis, Transplantation, Homologous, Unrelated Donors